[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:pancreatic-ductal-adenocarcinoma:gtpase-kras":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Pancreatic Ductal Adenocarcinoma","GTPase KRas",27,[8,16,23,29,36,42,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,151,157,164,170],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07522073","A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma",[12],"Phase 3","RECRUITING","2026-08-26T02:17:19.710918Z","2026-05-05T02:43:27.421423Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT03608631","iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:27.904411Z","2026-05-05T02:43:26.686443Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07409272","A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer",[12],"2026-08-26T02:15:25.633039Z","2026-04-29T02:57:57.145671Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05382559","A Study of ASP3082 in Adults With Advanced Solid Tumors",[33],"Phase 1","2026-08-26T02:16:46.951087Z","2026-07-05T05:32:16.801787Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06917079","BBO-11818 in Adult Subjects With KRAS Mutant Cancer",[33],"2026-08-26T02:18:35.425468Z","2026-07-05T05:32:16.701709Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07629960","A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations",[20],"2026-08-26T02:15:38.131683Z","2026-06-06T00:48:49.532877Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06835569","A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations",[33],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:29.166414Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT07094113","AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",[33],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.028170Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05379985","Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",[20],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:29.015195Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06179160","A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",[33],"2026-08-26T02:16:42.787115Z","2026-05-05T02:43:28.983627Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07020221","A Phase 1\u002F2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",[20],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:28.705701Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07094204","A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",[33],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.482220Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06128551","Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors",[20],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:28.404529Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06586515","MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",[33],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.316565Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT07349537","Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors",[33],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:27.730554Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06040541","Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors",[33],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:27.518589Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07223047","A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",[20],"2026-08-26T02:18:55.570428Z","2026-05-05T02:35:31.728570Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07252479","Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations",[33],"2026-08-26T02:16:01.910993Z","2026-06-16T05:54:07.937487Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT06764771","A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",[33],"2026-08-26T02:15:10.362237Z","2026-06-04T01:30:07.895587Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06026410","KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",[33],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.472498Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT07148128","Phase 1\u002F2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.",[20],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:28.963256Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT07064018","Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies",[20],"2026-08-26T02:16:08.402952Z","2026-05-05T02:35:31.867839Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":149,"content_modified":150},"NCT07644559","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer",[148],"Phase 2","2026-08-26T02:17:17.791881Z","2026-06-14T18:39:22.263618Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05630989","A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy",[],"2026-08-26T02:18:18.766496Z","2026-05-13T02:55:06.366215Z",{"nct_id":158,"title":159,"phases":160,"status":161,"updated_at":162,"content_modified":163},"NCT06015724","Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer",[148],"ACTIVE_NOT_RECRUITING","2026-08-03T02:21:37.915430Z","2026-06-18T12:24:02.339098Z",{"nct_id":165,"title":166,"phases":167,"status":161,"updated_at":168,"content_modified":169},"NCT07023731","A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation",[20],"2026-08-03T03:16:06.901903Z","2026-05-05T02:43:26.962034Z",{"nct_id":171,"title":172,"phases":173,"status":161,"updated_at":174,"content_modified":175},"NCT06447662","A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",[33],"2026-08-03T03:38:39.261584Z","2026-05-05T02:43:29.038880Z"]